Want to see SE:XSPRAY full AI Analyst Report?
XSPRAY Stock Chart & Stats
kr15.26
kr0.28(1.83%)
At close: 4:00 PM EDT
kr15.26
kr0.28(1.83%)
Day’s Range― - ―
52-Week Rangekr14.16 - kr62.33
Previous CloseN/A
Volume28.64K
Average Volume (3M)297.70K
Market Cap
kr800.39M
Enterprise Valuekr1.31K
Total Cash (Recent Filing)kr120.72M
Total Debt (Recent Filing)kr147.85M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.20
Shares Outstanding47,416,573
10 Day Avg. Volume602,659
30 Day Avg. Volume297,696
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)kr95.00M
Bulls Say, Bears Say
Bulls Say
Proprietary HyNap Formulation TechnologyHyNap is a durable technical asset that improves solubility and bioavailability for small molecules. As a platform technology it can enable formulation-based patent protection, reduce development risk versus novel targets, and support licensing or partner deals across multiple candidates.
Focused Strategy On Improved Versions Of Oncology DrugsTargeting known oncology actives with improved formulations shortens de-risking relative to novel mechanisms, leveraging existing clinical and market knowledge. This focus aligns with persistent oncology demand and can accelerate commercialization or partnering opportunities.
Equity Cushion With Moderate LeverageA sizeable equity base and moderate reported leverage provide a multi-quarter runway and some financial flexibility to fund R&D. This cushion reduces immediate insolvency risk and supports the company through clinical development phases while pursuing partnerships or financing.
Bears Say
No Revenue Across Reporting PeriodsThe persistent absence of product revenue means the business lacks commercial validation and must rely on financing to fund operations. Over months this drives recurring dilution or debt needs and demonstrates limited proven ability to monetize the technology.
Consistent Negative Cash Flow And Cash BurnSustained negative operating and free cash flow indicate the company is burning cash to fund development. Even with some improvement versus 2025, FCF remains negative and tracks net losses, tightening financing needs and limiting capacity to scale without new capital.
Rising Debt And Negative Returns On EquityDebt increasing from prior low levels while ROE is deeply negative signals capital erosion and growing financing obligations. Rising leverage amid ongoing losses raises refinancing and interest-service risks, constraining strategic optionality over the medium term.
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr14.16 and its highest was kr62.33 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr800.39M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Aug 05, 2026 which is today.
How were Xspray Pharma AB’s earnings last quarter?
Currently, no data Available
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Cantargia AB
―